Post-diagnostic ACE-inhibitor users had a reduced ovarian cancer-specific death risk (HR 0.55, 95% CI: 0.36–0.83), the results also showed better ovarian cancer survival in higher dose users (HR 0.46, 95% CI: 0.28–0.77, p for trend 0.002). Here, ACE is linked to ovarian cancer.